For Media: UK Press Releases

This page contains resources intended for journalists only. For media enquiries about our press releases please contact ukmediaenquiries@bayer.com

Area
Topic
SearchYour SelectionClear All
Your Selection
Clear All
Bayer starts Phase I study with SOS1 inhibitor in patients with advanced KRAS-mutated tumours
Bayer Launches Berocca® Mind to Support Your Memory With Spanish Sage
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies
Bayer submits application to MHRA for elinzanetant to treat moderate to severe vasomotor systems associated with menopause in women
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with a common form of heart failure with high unmet medical need
Darolutamide meets primary endpoint in Phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer